How High Is "Too High"? Using a Baby's Eyes to Set a Safer Blood-Sugar Target

A plain-language look at a pilot study that links blood sugar in very premature babies to a serious eye condition

Doctors have long known that very premature babies often have high blood sugar, but they have never agreed on how high is too high. A new pilot study offers a fresh way to answer that question — by letting a serious eye disease of prematurity reveal where the danger begins. It found that blood-sugar levels well below the point at which most intensive-care units start treatment were linked to the severe form of that eye disease, a signal that deserves further study [1].

Why This Question Matters

When a baby is born many weeks early, almost every body system is unfinished, and keeping blood sugar steady is one of the daily balancing acts in a neonatal intensive care unit (NICU). Premature babies frequently run high blood sugar — a condition called hyperglycemia — because their bodies cannot yet regulate it well, because they receive sugar through their veins for nutrition, and because illness and certain medicines push it up [2]. For decades, the tricky part has not been detecting high sugar but deciding when to act on it. Push the sugar down too aggressively, usually with insulin, and you risk low blood sugar, which can be even more dangerous for a developing brain. Wait too long, and you may allow harm you could have prevented. Because no one has known exactly where the harmful level lies, practice varies widely from one hospital, and even one doctor, to the next [3].

How Families and Doctors Used to Face This

For most of the history of newborn intensive care, the "target" blood sugar for a premature baby has been a best guess handed down through experience rather than a number proven to protect against a specific harm. Guidelines have listed a broad acceptable range and described the many causes of high sugar, while openly admitting that the threshold above which damage occurs was unknown. Parents, understandably, have often been told that a somewhat elevated sugar reading is being "watched" — true, but unsatisfying, because there was no clear line to watch for. The result was a strange gap: one of the most carefully monitored numbers at the bedside had no agreed meaning. This pilot study is an attempt to finally give that number a meaning grounded in a real outcome that matters to the baby.

The researchers borrowed their idea from adult diabetes. In adults, the well-known blood test hemoglobin A1C — a measure of average blood sugar over time — has a diagnostic cutoff of 6.5%. That number was not invented out of thin air; it was chosen because it predicts diabetic eye disease, a concrete, measurable form of harm [4]. The team wondered whether the same trick could work for premature babies: pick an eye disease that these babies are already screened for, and let it define what counts as dangerous blood sugar.

The Eye Disease at the Center of the Study

That eye disease is retinopathy of prematurity, or ROP. It affects the developing blood vessels at the back of the eye in babies born very early, and in its severe form it can threaten sight. Every baby born before 30 weeks is already examined regularly for ROP, so it is a well-understood and closely tracked condition [5]. Importantly, earlier research had already suggested that high blood sugar makes ROP more likely, even after accounting for how premature the baby is and how much oxygen they received — a link confirmed when many studies were pooled together [6]. What no one had done was turn the question around and ask the eye to name the blood-sugar level at which severe disease becomes likely.

It is worth pausing on why this matters so much to families. A premature baby in the NICU may have their blood sugar checked many times a day, and parents often watch those numbers closely, searching for reassurance. But without a proven safe target, even the care team could not always say what a given number truly meant for the baby's future. A study that ties blood sugar to a real, countable outcome — an eye condition doctors already look for — is a step toward giving those bedside numbers genuine meaning, so that one day families and doctors can act on them with more confidence.

What the Study Did and Found

The study followed 98 babies born before 30 weeks in a single NICU in Michigan between 2022 and 2024 [1]. The researchers did not change anyone's care; they simply watched. Over each baby's first month, they tracked two measures of average blood sugar: the ordinary running average of glucose readings, and a glycated-hemoglobin test similar to the adult A1C, carefully adapted because blood transfusions — common in the tiniest babies — can throw the test off.

Of the 98 babies, 20 developed the severe form of ROP. In those babies, both blood-sugar measures were clearly higher than in babies without the disease, and they rose step by step from no disease to mild disease to severe disease. When the researchers calculated the tipping points, they found that an average glucose of about 93.8 mg/dL and an A1C of about 5.66% best flagged the babies who went on to develop severe ROP — and each did so correctly 94% of the time when the marker was elevated [1].

The striking part is how low those numbers are. Most NICUs would not consider an average glucose in the 90s to be a problem at all; treatment with insulin usually does not begin until readings are much higher — often 150 mg/dL or more [3]. This study raises the possibility that blood-sugar levels we currently think of as perfectly fine might still carry some risk for the developing eye. That fits with an earlier French study, which found that sugar staying above roughly 126 mg/dL for more than nine days predicted severe ROP — again, below the usual point of treatment [7].

What the Findings Mean for Families

Here is the most important thing for parents to understand: this study found a link, not a cause, and it cannot yet change how any baby is treated. The babies who developed severe ROP were also the most premature and the sickest overall — they had more infections, more breathing problems, and more time on oxygen. So it is very hard to know how much the blood sugar itself mattered versus simply being a marker of how fragile these particular babies were. The study was small, done at one hospital, and was not designed to untangle those threads.

Just as important, the obvious "fix" — using more insulin to push blood sugar down toward 94 — could do real harm. Insulin can drive blood sugar too low, and studies of tighter sugar control in premature babies have not shown clear benefit and have raised safety concerns [8]. No responsible team would start treating a glucose of 94 based on this study. If your baby's team mentions blood sugar in the 90s or low 100s, the right takeaway is not alarm but attention: it is a number worth keeping an eye on, weighed carefully against the danger of going too low.

It also helps to know why blood sugar might affect the eye at all. In severe ROP, the retina grows abnormal, fragile blood vessels, driven by a signaling molecule called VEGF. High blood sugar is known to stir up this same process and add to the stress on delicate tissues, which makes the link biologically believable rather than a statistical fluke [9]. At the same time, many babies developed severe ROP without any sign of high blood sugar, which tells us that sugar is only one of several roads to the disease. The best-known cause remains the delicate balancing act of giving premature lungs enough oxygen without giving the eyes too much. That is why researchers describe high blood sugar as a possible contributor to ROP in some babies rather than the single explanation, and why any future treatment would need to be tested carefully rather than assumed to work.

What Researchers Are Working On Next

The authors are refreshingly clear that their numbers are a starting point, not a finish line. The next step is a larger study across many hospitals, big enough to separate the effect of blood sugar from the effects of extreme prematurity, oxygen, and infection. If a threshold holds up, the harder question follows: would gently lowering blood sugar toward that target actually prevent severe eye disease — and could it be done without causing the low-sugar episodes that everyone fears [8]? Answering that will likely require continuous glucose monitors, which track sugar minute by minute, and a blood test for average sugar that is properly validated for newborns [10]. For now, the study's real contribution is to reopen a long-neglected question — how high is too high for a premature baby's blood sugar — with a clever enough method that the bigger, more definitive studies are worth doing. For families, it is a reminder that even the most familiar numbers on the monitor are still being understood, and that careful research is steadily working to make that care safer.

References

  1. Movsas TM, Nadernejad C, Prentice J, Dudick B, Pribyl A, Sanfilippo L, Geddie BE. Identifying neonatal hyperglycemia thresholds in preterm infants based on retinopathy of prematurity outcomes: proof-of-concept study. Front Pediatr. 2025;13:1688879. doi:10.3389/fped.2025.1688879 ↩
  2. Angelis D, Jaleel MA, Brion LP. Hyperglycemia and prematurity: a narrative review. Pediatr Res. 2023;94(3):892–903. doi:10.1038/s41390-023-02628-9 ↩
  3. Ogilvy-Stuart AL, Beardsall K. Management of hyperglycaemia in the preterm infant. Arch Dis Child Fetal Neonatal Ed. 2010;95(2):F126–31. doi:10.1136/adc.2008.154716 ↩
  4. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. (DCCT Research Group). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. doi:10.1056/NEJM199309303291401 ↩
  5. Jefferies AL. Retinopathy of prematurity: an update on screening and management. Paediatr Child Health. 2016;21(2):101–8. doi:10.1093/pch/21.2.101 ↩
  6. Rath CP, Shivamallappa M, Muthusamy S, Rao SC, Patole S. Outcomes of very preterm infants with neonatal hyperglycaemia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2022;107(3):1–12. doi:10.1136/archdischild-2020-321449 ↩
  7. Kermorvant-Duchemin E, Le Meur G, Plaisant F, Marchand-Martin L, Flamant C, Porcher R, et al. Thresholds of glycemia, insulin therapy, and risk for severe retinopathy in premature infants: a cohort study. PLoS Med. 2020;17(12):e1003477. doi:10.1371/journal.pmed.1003477 ↩
  8. Lee JH, Hornik CP, Testoni D, Laughon MM, Cotten CM, Maldonado RS, et al. Insulin, hyperglycemia, and severe retinopathy of prematurity in extremely low-birth-weight infants. Am J Perinatol. 2016;33(4):393–400. doi:10.1055/s-0035-1565999 ↩
  9. Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122(1):200–10. doi:10.1016/j.ophtha.2014.07.050 ↩
  10. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, Ong K, et al. Prevalence and determinants of hyperglycemia in very low birth weight infants: cohort analyses of the NIRTURE study. J Pediatr. 2010;157(5):715–9.e3. doi:10.1016/j.jpeds.2010.04.032 ↩